Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP), was interviewed on Facebook Live yesterday in conjunction with the company ringing the NASDAQ exchange closing bell.
Dr. Beebe discussed Titan’s Probuphine implant, which was approved by the FDA earlier this year for the treatment of opioid addiction, and its sales and marketing partner, Braeburn Pharmaceuticals.
Probuphine was developed with Titan’s ProNeura drug delivery platform, which overcomes issues of drug compliance by patients. Dr. Beebe also discussed Titan’s pipeline and how ProNeura is being used to develop long-term treatments for Parkinson’s disease and hypothyroidism.
The interview can be viewed here.